CompletedN/ADMT
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Sponsored by Bristol-Myers Squibb
NCT ID
NCT05658601
Target Enrollment
104 participants
Start Date
2023-07-14
Est. Completion
2025-07-03
About This Study
The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions Studied
Eligibility
Age:18 Years - 55 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Patients with RRMS according to 2017 revised McDonald criteria * Patients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollment * Patient with a MRI performed within three months before the enrollment * Patient eligible to ozanimod according to SmPC Exclusion Criteria: * Patients with clinical forms of MS other than RRMS * Patients unable to participate for various reasons * Patients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objective * Contraindications to ozanimod according to SmPC Other protocol-defined Inclusion/Exclusion Criteria apply.
Study Locations (1)
Local Institution - 0001
Isernia, Italy